HC Wainwright Cuts Iterum Therapeutics (NASDAQ:ITRM) Price Target to $5.00

Iterum Therapeutics (NASDAQ:ITRM – Get Free Report) had its price target decreased by HC Wainwright from $6.00 to $5.00 in a research report issued on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 313.22% from the company’s previous close. Iterum Therapeutics […]

Leave a Reply

Your email address will not be published.

Previous post Mineralys Therapeutics (NASDAQ:MLYS) Rating Reiterated by HC Wainwright
Next post AnaptysBio (NASDAQ:ANAB) Given New $30.00 Price Target at Truist Financial